Skip to main content

The independent medical news service

15-10-2019 | Oncology | News | Article

TITAN-RCC showcases tailored immunotherapy approach

Results from the TITAN-RCC trial add support for the use of ipilimumab alongside nivolumab in patients with intermediate- or high-risk advanced renal cell carcinoma, showing that a personalized strategy is feasible for nonresponders.

15-10-2019 | Oncology | News | Article

Value of blood-based screening for ALK fusions shown in patients with NSCLC

Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

14-10-2019 | Oncology | News | Article

Olaparib–temozolomide combination has ‘substantial’ activity in relapsed SCLC

A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.

14-10-2019 | Oncology | News | Article

SORCE rules out adjuvant sorafenib for RCC

Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.

11-10-2019 | Oncology | News | Article

IMpower110: OS boost with first-line atezolizumab in PD-L1-high metastatic NSCLC

An interim analysis of the IMpower110 study has demonstrated an overall survival improvement with atezolizumab versus chemotherapy in treatment-naïve patients with stage IV non-small-cell lung cancer and high levels of PD-L1 expression.

10-10-2019 | Oncology | Highlight | Article

PROfound paves the way for precision medicine in mCRPC

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

10-10-2019 | Oncology | News | Article

​​​​​​​Nivolumab–ipilimumab an option for untreated, advanced NSCLC regardless of PD-L1 levels

Individuals with advanced non-small-cell lung cancer derive an overall survival benefit from first-line treatment with nivolumab plus ipilimumab irrespective of PD-L1 expression, report the CheckMate 227 investigators.

10-10-2019 | Oncology | News | Article

Early data look promising for sacituzumab govitecan in metastatic urothelial carcinoma

Initial results from the phase II TROPHY-U-01 trial confirm the antitumor activity of sacituzumab govitecan in patients with metastatic urothelial carcinoma that has progressed after platinum chemotherapy or checkpoint inhibition.

09-10-2019 | Oncology | News | Article

No survival improvement with pembrolizumab in malignant pleural mesothelioma

Pembrolizumab does not confer a progression free survival or overall survival advantage in previously treated patients with advanced malignant pleural mesothelioma, suggest findings from the PROMISE-meso trial.

08-10-2019 | Oncology | News | Article

HRQoL data bolster positive survival findings from TITAN study

Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.

08-10-2019 | Oncology | News | Article

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

08-10-2019 | Oncology | News | Article

Ultra-hypofractionated SBRT has low acute toxicity in localized prostate cancer

Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.

07-10-2019 | Oncology | News | Article

PFS boost with atezolizumab–chemotherapy in advanced urothelial carcinoma

Adding atezolizumab to chemotherapy significantly prolongs progression-free survival in the first-line advanced urothelial cancer setting, according to the IMvigor130 trial results presented at the ESMO Congress 2019.

04-10-2019 | Oncology | News | Article

Metformin prolongs PFS in patients with EGFR-mutated lung adenocarcinoma

Research published in JAMA Oncology shows that patients with EGFR-mutated lung adenocarcinoma have prolonged progression free survival when tyrosine kinase inhibitor treatment is supplemented with metformin.

03-10-2019 | Oncology | News | Article

CASPIAN: Adding durvalumab to chemotherapy improves SCLC PROs

The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.

30-09-2019 | Oncology | News | Article

CARD results support cabazitaxel use in mCRPC

Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.

29-09-2019 | Oncology | News | Article

FLAURA shows OS boost with osimertinib in advanced NSCLC

The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR-mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.

28-09-2019 | Oncology | News | Article

Apalutamide may improve OS in men with nonmetastatic CRPC

An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.

28-09-2019 | Oncology | News | Article

STAMPEDE shows docetaxel benefit regardless of metastatic burden

Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.

26-09-2019 | Oncology | News | Article

Male infertility linked to increased prostate cancer risk

The risk for prostate cancer is 30–60% higher in men who father children through assisted reproduction than in those who conceive naturally, shows a nationwide study conducted in Sweden.

Image Credits